Alumis Inc
ALMS4.080USD
-0.050-1.21%
Market hours （ET）Quotes delayed by 15 min
221.98MMarket Cap
LossP/E TTM
More Details of Alumis Inc Company
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Company Info
Ticker SymbolALMS
Company nameAlumis Inc
IPO dateJun 28, 2024
CEOMr. Martin Babler
Number of employees168
Security typeOrdinary Share
Fiscal year-endJun 28
Address280 East Grand Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16502316625
Websitehttps://www.alumis.com/
Ticker SymbolALMS
IPO dateJun 28, 2024
CEOMr. Martin Babler
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Revenue Breakdown
FY2025Q1
No Data
By RegionUSD
Name
Revenue
Proportion
United States
17.39M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jul 29
Updated: Tue, Jul 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Foresite Capital Management, LLC
15.83%
Ayur Maya Capital Management Company, L.P.
15.77%
Samsara BioCapital, LLC
5.00%
VenBio Partners LLC
2.90%
Cormorant Asset Management, LP
2.24%
Other
58.26%
Shareholders
Shareholders
Proportion
Foresite Capital Management, LLC
15.83%
Ayur Maya Capital Management Company, L.P.
15.77%
Samsara BioCapital, LLC
5.00%
VenBio Partners LLC
2.90%
Cormorant Asset Management, LP
2.24%
Other
58.26%
Shareholder Types
Shareholders
Proportion
Private Equity
34.50%
Venture Capital
7.06%
Investment Advisor
5.68%
Hedge Fund
4.34%
Investment Advisor/Hedge Fund
2.14%
Individual Investor
0.64%
Bank and Trust
0.43%
Research Firm
0.34%
Sovereign Wealth Fund
0.21%
Other
44.65%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
149
53.14M
55.36%
+11.35M
2025Q1
136
45.24M
77.97%
+3.71M
2024Q4
112
45.08M
95.45%
+8.63M
2024Q3
90
35.83M
75.90%
+3.97M
2024Q2
36
30.85M
69.04%
+30.85M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Foresite Capital Management, LLC
15.20M
15.83%
+5.22M
+52.25%
May 21, 2025
Ayur Maya Capital Management Company, L.P.
15.14M
15.77%
+4.49M
+42.21%
May 21, 2025
Samsara BioCapital, LLC
4.80M
5%
+1.53M
+46.99%
May 21, 2025
VenBio Partners LLC
2.79M
2.9%
--
--
Mar 31, 2025
Cormorant Asset Management, LP
2.15M
2.24%
--
--
Mar 31, 2025
SR One Capital Management, LP
1.96M
2.04%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
1.56M
1.63%
--
--
Mar 31, 2025
Nextech Invest, Ltd.
1.48M
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.35M
1.41%
+300.30K
+28.57%
Mar 31, 2025
The Vanguard Group, Inc.
937.20K
0.98%
+99.01K
+11.81%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 ETF
0.01%
View more
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Micro-Cap ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
